IDEAYA Biosciences Business Summary

IDEAYA Biosciences, Inc. (IDYA) is a precision medicine oncology company that generates revenue primarily through strategic collaboration and licensing agreements with global pharmaceutical partners, most notably an exclusive license with Servier for its lead asset, darovasertib. The company’s business model is centered on two primary segments: synthetic lethality, which exploits genetic vulnerabilities in cancer cells, and next-generation antibody-drug conjugates (ADCs). As of early 2026, IDEAYA maintains a robust financial position with approximately $1.1 billion in cash, funding operations into 2030 as it advances four registrational trials across indications such as uveal melanoma and neuroendocrine cancer. Within the competitive landscape, IDEAYA competes with mid-cap biotechnology firms like Beam Therapeutics, Viridian Therapeutics, and Apellis Pharmaceuticals, distinguishing itself as a leader in the synthetic lethality niche with a high-density pipeline of first-in-class clinical assets. Founded in 2015 by CEO Yujiro S. Hata, an industry veteran and former Executive-in-Residence at 5AM Ventures, the leadership team comprises executives with significant pedigrees from top-tier financial and pharmaceutical institutions. The executive suite includes Chief Financial Officer Joshua Bleharski, who joined in 2025 from J.P. Morgan’s healthcare investment banking group; Chief Technology Officer Paul A. Barsanti, Ph.D., who leads drug discovery; and Chief Scientific Officer Michael White, Ph.D., formerly of Pfizer. In February 2026, the company further strengthened its clinical strategy by appointing Dr. Theodora Ross, previously a Vice President at AbbVie, as Chief Development Officer. IDEAYA is backed by a prestigious roster of institutional investors and board members, including 5AM Ventures, Google Ventures (GV), Canaan Partners, and Chairman Terry Rosen, Ph.D., the CEO of Arcus Biosciences.